Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
A study found that younger generations are aging faster biologically, increasing their risk of early-onset cancers. The study linked accelerated aging in immune systems and fat tissue to higher risks of lung and colorectal cancer.
Dr. Nowicki's research aims to develop a next-generation CAR-T cell therapy targeting GD2, a protein found on osteosarcoma cells, with enhanced immune-signaling molecule TNF-alpha. The grant will support preclinical studies to evaluate safety and effectiveness in laboratory and animal models.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
Researchers develop AI framework using principles of superposition and entanglement to tailor cancer treatment to patients' entire molecular background. The technique predicts health outcomes and suggests genes to target, outperforming standard biomarkers in clinical trials.
Researchers have developed a polymer-based microring resonator array with over 40 elements, demonstrating broadband acoustic detection and fine spatial resolution. The system achieved strong correspondence with biological structures, including blood vessel regions, in imaging mouse prostate tissue.
The article explores ways clinicians can deliver care tailored to each patient's unique needs, priorities, and identities. Research highlights the importance of considering life transitions in supporting adolescents and young adults with cancer.
Researchers developed an AI-powered platform to track drug responses across thousands of patient-derived organoids, enabling real-time monitoring and analysis of tumor heterogeneity. The platform successfully measured how tumor organoids responded to drug treatment, providing a detailed view of treatment responses at the level of indiv...
A research team from the University of Liège uncovered a previously unrecognized mechanism that promotes cancer cell survival under therapeutic pressure. Cancer cells reprogram their lipid metabolism to sustain proliferation, with key enzyme SCD1 cooperating with epigenetic regulator HDAC2 to support tumor growth.
Researchers at the University of Texas MD Anderson Cancer Center discovered a new approach to help overcome immunotherapy resistance. Copper-induced cell death, known as cuproptosis, activates the immune system and can be combined with anti-PD-L1 immunotherapy to slow tumor growth.
A target trial emulation study found that delaying treatment of moderate pre-cancerous cervical cells (CIN 2) does not increase three-year cancer risk and reduces unnecessary excisions. The study suggests it may be safe to delay treatment, especially for lower-risk CIN 2, by adopting careful follow-up strategies.
Researchers found that patients often wait an average of four weeks for biomarker test results, with the first step taking up to 23 days to order testing. This delay can lead to mismatched therapies, toxic side effects, and reduced treatment options, emphasizing the need for improved testing turnaround times.
A USC-led team has developed a way to grow and genetically engineer progenitor cells that give rise to macrophages, a type of immune cell promising for cancer immunotherapies. The team successfully expanded these cells in the laboratory and engineered them to target specific cancer markers.
Researchers at UCL and Great Ormond Street Hospital have successfully treated a deadly childhood liver disease using mice with a healthy version of the VPS33B gene. The treatment, which specifically targeted liver cells, showed no harm and improved liver function in mice.
A spatial map of muscle-invasive bladder cancer reveals organized tumor cell states, immune environments, and therapeutic vulnerabilities. Luminal-like cells are found in tumor cores with relevant therapeutic markers, while basal-like cells near margins show signs of aggressiveness. This study guides treatment strategies by accounting ...
Researchers developed a quick and non-invasive imaging method combined with machine learning to detect precancerous lesions and early-stage cancers in the uterus. The method uses 3D OCT images to provide clear differences among normal tissue, benign endometrium, high-risk precancerous lesions, and endometrial cancer at different stages.
Researchers have identified a rare genetic mutation associated with blood cancers, finding that it does not always lead to disease development. The study provides insight into the initial phases of the disease and may eventually lead to improved patient outcomes through targeted monitoring.
Researchers developed an mRNA vaccine that targets neuroblastoma, delaying tumour development by 10-11 days and reducing tumour size by 70% in preclinical models. The vaccine uses peptide nanoparticles to target GPC2, a protein found on the surface of neuroblastoma cells.
A hospital-based study in India found that higher coffee consumption and meat intake were associated with lower odds of prostate cancer. The researchers identified potential biological mechanisms behind these findings, but note that the relationship between diet and prostate cancer is complex and warrants further investigation.
Researchers found that eliminating a protein called DHHC3 in melanoma cells led to increased oxidative stress, cellular senescence, and activation of anti-tumor immune cells. This suggests that DHHC3 plays an immunoregulatory role in melanoma growth.
A new clinical trial, SELECTmeso1, is investigating a personalized treatment for patients with a rare and aggressive form of cancer. The trial aims to improve outcomes for patients with a specific genetic biomarker, and if successful, could lead to future practice-changing trials.
Colorectal cancer cells exploit a specific mitochondrial complex, complex II, to buffer iron toxicity and prevent cell death. By knocking out this complex, researchers found that cancer cells were more susceptible to cell death, suggesting it as a promising target for drug development.
A nationwide population-based study found that individuals with neovascular age-related macular degeneration had a modest but statistically significant increase in overall cancer risk. However, the increased risk was only observed for specific malignancies, including thyroid, kidney, and prostate cancers.
Duke-NUS scientists have discovered that ageing muscle contributes to cancer growth by releasing fewer extracellular vesicles, which can be restored through exercise. The study also found changes in the composition of these particles with age, weakening protective signals against tumour development.
Magnus Hoffmann, a Gladstone scientist, has been recognized as a 2026 Pew Biomedical Scholar for his pioneering approach to advancing human health and medicine. His lab is developing an innovative immunotherapy platform to enhance the natural ability of the immune system to detect and respond to tumor-specific features.
A recent study reveals that cancer cells within tumors are genetically diverse, yet all carry the same core genetic changes. The research found that these changes occur in sudden bursts, creating distinct subpopulations that influence tumor aggressiveness and treatment response.
A new study has identified a two-protein complex involved in exporting R-loops, which triggers an immune response causing harmful inflammation. The study tested an approved drug called KPT-330 and found significant improvements in inflammation, liver damage, fat gain, muscle loss, and lifespan in preclinical models.
A team of researchers has identified a previously unknown vulnerability in KRAS-mutated pancreatic cancer cells, making them susceptible to necroptosis. Blocking the tumor cells' defense mechanism by inhibiting caspase-8 leads to significant cell death and reduced tumor growth.
A new division at the James Buchanan Brady Urological Institute will support research, education, and care for urological conditions. The gift will accelerate advancements in surgical training, imaging, and technology to improve patient outcomes.
Researchers found that CAR T cell therapy triggers a broad immune response in glioblastoma patients, with activated natural killer cells associated with better outcomes and longer overall survival. In contrast, high levels of immunosuppressive regulatory T cells and myeloid cells hinder the therapy's effectiveness.
A Phase I/II clinical trial of the HPV therapeutic vaccine PepCan found it to be well-tolerated, with mild injection-site reactions being the most common adverse events. However, the study did not demonstrate a reduction in head and neck cancer recurrence rates, likely due to its small sample size.
Researchers from ETH Zurich have developed a system that uses light to selectively destroy glucocorticoid receptors on tumour cells, making them vulnerable to attack. This approach could lead to more targeted and effective cancer treatments with fewer side effects.
Terasaki Institute researchers and key pioneers publish comprehensive review on glioma organoid models, proposing a foundational classification framework to guide translational brain tumor research. The review provides an overview of human glioma organoid systems and aims to address methodological heterogeneity in the field.
A new immunotherapy combination has shown promise in delaying cancer progression and improving survival for patients with multiple myeloma. The study found that nearly nine in 10 patients receiving the treatment experienced a shrinkage of their cancer, compared to about eight in 10 on standard treatment.
A study by the University of Barcelona discovered that differences in tumour microenvironment surrounding adenocarcinoma and squamous cell carcinoma largely depend on abundant benign cells called fibroblasts. This finding opens the door to develop more personalized therapies tailored to each tumour's specific characteristics.
A large-scale European study found that screening people with Li-Fraumeni syndrome can significantly reduce healthcare costs. The study showed that prevention costs per patient were roughly nine times lower than treatment costs, and patients who underwent regular screening had better clinical outcomes.
Recent advances in tumor microenvironment-responsive nanomedicines offer a promising strategy to address limitations of traditional cancer therapies. These smart carriers enable precise drug release and enhance therapeutic efficacy through structural transformations triggered by specific stimuli within the tumor microenvironment.
Researchers developed a two-pronged approach to encourage important conversations between patients with cancer and their oncologists about goals and preferences for care. The study found that combining reminders for both patients and providers at the right moment significantly increased serious illness conversations.
A new study from Karolinska Institutet found that neutrophils, a type of white blood cell, can dampen the effect of immunotherapy in cancer treatment. When neutrophils were absent, several immunotherapies became more effective, leading to increased T-cell activation and tumor shrinkage.
A large-scale study found dozens of genetic mutations linked to cancer type and ancestry, improving survival predictions in breast and glioma cancers. Combining ancestry data with tumour analyses enhances prediction accuracy, particularly for pancreatic cancer patients.
Researchers at UCSF built a robotic system to treat thousands of mini tumors, identifying shared features among persister cells that could help explain why cancer comes back. Nine drugs consistently weakened persister cells, suggesting common vulnerabilities.
Researchers at UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million NIH grant to develop advanced imaging and surgical strategies for improving glioblastoma outcomes. The team aims to use pH-based imaging to guide precise tumor removal and explore targeted therapies that target the tumor's acid-regulating systems.
A team of researchers has discovered large droplets of proteins known as condensates near inactive chromosome regions within the cell nucleus that are a feature of some cancer cells. The newly found condensates store excess gene-activating protein TEAD1, regulating its activity and preventing toxicity to the cell.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Researchers from Kyushu University discovered that the circadian clock protein BMAL1 drives macrophages towards a pro-inflammatory M1 state by activating inflammatory signaling pathways. This mechanism links the body clock to intracellular metabolism and immune function, offering new insights into treating inflammatory diseases.
Johanna Joyce, a leading tumor immunologist, has begun her two-year term as President of the European Association for Cancer Research. She will focus on strategic oversight, promoting broad scientific collaboration, dialogue, and training, while addressing issues such as gender disparities in science.
A new national analysis found that mesothelioma deaths and diagnoses continue to rise in the US, with little improvement in survival rates. The disease disproportionately affects women and several high-risk states tied to shipbuilding, mining, and legacy asbestos exposure.
Researchers developed a nanowire device that selectively captures cancer-related extracellular vesicles from the blood serum of ovarian cancer patients. The technology uses high-performance zinc oxide nanowires and achieves efficient capture of cancer biomarkers with minimal physical burden on patients.
Researchers at UC Irvine have discovered a mechanism that combines DNA damage and inflammatory signaling in tumor cells, potentially improving cancer treatment response. The study found that a combination of PARP inhibitors and TOP1 blockers triggers an 'alarm signal' inside cancer cells, alerting the immune system to eliminate them.
Researchers developed DNA tetrahedrons with Vitamin E-derived molecules for targeted cancer treatment, enhancing cellular uptake and improving anticancer efficacy. The modification triggered oxidative stress in cancer cells, leading to programmed cell death.
A new study found that HPV-DeepSeek, an ultrasensitive blood test, can identify patients with HPV-associated head and neck cancer who may benefit from additional treatments. The test detected circulating tumor DNA in 98.1% of patients at diagnosis, significantly improving detection rates compared to existing methods.
Researchers at MIT developed an ultrasound system that creates a real-time 3D representation of the object being imaged, making it easier to identify and analyze. The AR-VIU technology can be deployed in hospitals for tasks such as placing needles during biopsies, reducing training time and increasing accuracy.
A study published in JAMA Network Open found that high consumption of sugar-sweetened beverages was linked to an increased risk of liver cancer. In contrast, artificially sweetened beverage intake showed no significant association with liver cancer risk.
A new study published in Genes & Cancer identifies activated beta-catenin as a key driver of aggressive pediatric osteosarcoma progression. The researchers found that cells expressing active beta-catenin exhibited enhanced invasive capacity and cancer-associated traits, suggesting a potential therapeutic target for this aggressive cancer.
A University of Ottawa-led study has discovered a hidden network driving glioblastoma's aggressive growth, highlighting a promising target for next-generation therapies. The research reveals that a protein called OSMR plays a critical role in tumor progression and supports the survival of brain tumour stem cells.
Researchers found that extreme heat impacts daily life, access to care, and treatment-related decisions among people with cancer. Participants adapted by limiting outdoor activity, but these compromises affected health, independence, and quality of life.
Current evidence links dysregulated PTM systems to cancer biomarkers and therapeutic targets, offering a dynamic view of tumor cell state. PTM-based biomarkers may improve early detection, molecular subtyping, prognosis, and prediction of therapy response.
Researchers identified a potential therapeutic lever against advanced bladder cancer, exploiting iron-dependent tumor cell death and its upstream regulatory mechanisms. The study found that JS-K can induce ferroptosis in bladder cancer cells by damaging mitochondria and disturbing iron balance.
A new study links even moderate drinking to elevated risks of chronic diseases and premature death. The research provides a much-needed benchmark with findings that one drink per day above the daily limit increases the risk of death, disability, and chronic diseases.
A machine learning model called plasmaCHORD filters out biological noise in liquid biopsy samples, enabling clinicians to better match therapies to their patients' tumors. The model has been shown to improve the ability to distinguish tumor from white blood cell mutations in approximately 83% of cases.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.